Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab maintenance therapy in moderate to severe Crohn's disease
NL-OMON43994Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 44 and Safety of ustekinumab maintenance regimens. Started Oct 2012; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON43994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43994.